CTT Pharma CEO buys 10,900 shares at $0.048

Rhea-AI Filing Summary

CTT Pharmaceutical Holdings, Inc. (CTTH) reports that its reporting person, identified as a director and CEO of the company, purchased 10,900 shares of CTTH common stock on September 16, 2026 at $0.048 per share, bringing the reported direct holdings to 9,414,456 shares. No Rule 10b5-1 trading plan is indicated.

Insider Trade Summary

Net Buyer: 10,900 shares

Net Buy 1 txn

Insider CTT PHARMACEUTICAL HOLDINGS, INC.

Role CEO

Bought 10,900 shs ($523.20)

Type	Security	Shares	Price	Value
Purchase	CTTH	10,900	$0.048	$523.20

Holdings After Transaction: CTTH — 9,414,456 shares (Direct)

Key Figures

Shares purchased: 10,900 shares Purchase price: $0.048 per share Shares held after transaction: 9,414,456 shares +2 more

5 metrics

Shares purchased 10,900 shares Non-derivative acquisition on September 16, 2026

Purchase price $0.048 per share Price for CTTH shares bought on September 16, 2026

Shares held after transaction 9,414,456 shares Direct holdings reported following the purchase

Number of buy transactions 1 transaction Buy transactions reported in this Form 4

Net buy-sell shares 10,900 shares Net effect of reported transactions is a net buy

Key Terms

non-derivative, open market or private transaction, Rule 10b5-1 trading plan

3 terms

non-derivative financial

"classified as a non-derivative acquisition of CTTH common stock"

open market or private transaction financial

"Purchase in open market or private transaction"

Rule 10b5-1 trading plan regulatory

"the Rule 10b5-1 checkbox is not affirmed"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CTTH report on this Form 4?

CTT Pharmaceutical Holdings, Inc. reported that its reporting person, identified as a director and CEO, purchased 10,900 CTTH shares on September 16, 2026 as a non-derivative transaction, increasing the reported direct stake to 9,414,456 shares.

At what price were the CTTH shares purchased in this Form 4?

The reported purchase price was $0.048 per share for the 10,900 CTTH shares bought on September 16, 2026 in a non-derivative open-market or private transaction.

How many CTTH shares does the reporting person hold after this transaction?

After the September 16, 2026 purchase, the reporting person is shown as directly holding 9,414,456 CTTH shares.

Was the CTTH insider trade made under a Rule 10b5-1 plan?

No. The Form 4 indicates that the Rule 10b5-1 checkbox is not affirmed, so the reported September 16, 2026 purchase was not disclosed as being made under a Rule 10b5-1 trading plan.

Is this CTTH Form 4 transaction a derivative or non-derivative trade?

The Form 4 classifies the September 16, 2026 transaction as a non-derivative acquisition of CTTH common stock, with no accompanying derivative security exercises or conversions reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 01:20 PM Accepted by SEC EDGAR 09/16/2026 - 01:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CTT PHARMACEUTICAL HOLDINGS, INC.

(Last) (First) (Middle)

1646 W. SNOW AVE SUITE 138

(Street)

TAMPA FLORIDA 33606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CTT PHARMACEUTICAL HOLDINGS, INC. [ CTTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
CTTH	09/16/2026		P		10,900	A	$0.048	9,414,456	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Ryan Khouri	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)